Clinical and Biomarker Changes in Dominantly Inherited Alzheimers Disease
NEJM 367:795-804,864, Bateman, R.J.,et al, 2012
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients with Early Alzheimer Disease
Neurol 98:e968-e977, Whittington, M.D.,et al, 2022
Neuro R� score
Neurol 94:e1614-e1621, Peacock, S.H.,et al, 2020
PET Imaging for Alzheimer Disease: Are Its Benefits Worth the Cost?
JAMA 309:1099-1100, Mitka, M., 2013
Effectiveness of Adding Memantine to an Alzheimer Dementia Treatment Regimen Which Already Includes Stable Donepezil Therapy: A Critically Appraised Topic
The Neurologist 17:121-123, Riordan,K.C.,et al, 2011
Cost Effectiveness of Warfarin Versus Aspirin in Patients Older Than 75 Years With Atrial Fibrillation
Stroke 42:1717-1721, Jowett, S.,et al, 2011
Comparative Analysis of Therapeutic Options Used for Myasthenia Gravis
Ann Neurol 68:797-805, Mandawat,A.,et al, 2010